- Alkermes (NasdaqGS: ALKS) has begun a pivotal Phase 2 trial of ALKS 7290 as an adjunctive treatment for major depressive disorder.
- The study will assess ALKS 7290, an orexin 2 receptor agonist, in patients already receiving standard antidepressant therapies.
- The new trial adds a late-stage neuropsychiatric asset to Alkermes' pipeline focused on areas of unmet need in mood disorders.
- The launch of this Phase 2 trial for ALKS 7290 matters, but investors should weigh it against Alkermes' broader risk profile. We have also spotted 3 warning signs (1 major) worth knowing about at Alkermes.
For readers interested in more ideas tied to brain health treatments and digital tools, the next stop is 39 profitable AI stocks that aren't just burning cash.
Alkermes, a US based biopharmaceutical group with a market cap of about $7.6b, develops and commercializes treatments targeting unmet medical needs in areas like mood disorders. This gives the new MDD program direct relevance to its core research focus.
2 things going right for Alkermes that this headline doesn't cover.
ALKS 7290 pushes Alkermes’ orexin story deeper into psychiatry
For Alkermes, this MDD study tightens the Narrative link between its existing neuroscience franchise and the broader orexin 2 receptor agenda. The new trial directly supports the catalyst that orexin agonists such as ALKS 7290 could expand the addressable market beyond sleep disorders into larger psychiatric indications like ADHD and depression, potentially giving the business another shot at multi indication revenue streams. It does not change the core trade off flagged in the Narrative, where higher R&D and integration costs leave the group guiding to a GAAP net loss in 2026 while leaning on positive EBITDA to fund this kind of work.
See how these catalysts shape Alkermes' path to a $56.56 fair value.
The key signpost from here is the first readout from this six week Phase 2 MDD trial, since the safety and MADRS and CGI S symptom data will show whether ALKS 7290 justifies progression toward late stage depression studies alongside the separate 312 patient ADHD Phase 2 program already running.
What are analysts really assuming about where Alkermes ends up a few years from now?
Short term headlines rarely spell out where detailed models think this business could land on earnings, cash flow and balance sheet shape several years down the line. See where analysts expect Alkermes to be in a few years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com